Posted on April 18, 2022 by Sitemaster
This coming Friday, April 22, at 11:00 am Eastern / 8 am Pacific, there will be an important new educational opportunity for the prostate cancer patient and patient advocacy community: Your Voice in the Future of Active Surveillance, coordinated by Active Surveillance Patients International (ASPI) and AnCan and and supported by many other prostate cancer patient advocacy groups. To register, please click here.
More than 50 percent of all patients currently being diagnosed with prostate cancer are now understood to be appropriate for initial management on active surveillance, without immediate invasive treatments such as surgery or radiation therapy. A significant percentage of those men may never, ever need invasive treatment at all.
Optimizing the accuracy of the diagnosis of such men — and then ensuring high quality monitoring over time (while minimizing the need for unnecessary biopsies) has become a priority for many in the prostate cancer research community who will be participating as speakers and discussants in this informational program. And the patient community has a huge potential role to play in moving these initiatives forward.
Your voice may be critical in moving these initiatives forward over the next three to five years.
Filed under: Uncategorized | 3 Comments »
Posted on November 30, 2021 by Sitemaster
About 100 patients, clinicians, and others are already registered as attendees at the conference on
Click on the link above for more information and to register. There is still plenty of time to join us.
The conference will take place from 12:00 pm to 4:00 pm Eastern time on Monday, December 13 AND on 12:00 pm to 4:00 pm on Thursday, December 16.
Continue reading →
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Leave a comment »
Posted on November 12, 2021 by Sitemaster
Registration is now OPEN for the upcoming conference on future research into the use of active surveillance for men with favorable-risk forms of localized prostate cancer:
Click on the link above for more information and to register. … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on October 20, 2021 by Sitemaster
As many readers will already be aware, the National Comprehensive Cancer Network (NCCN) has recently removed the word “preferred” from its statement regarding the use of active surveillance (AS) as an appropriate form of management of men with low-risk forms of localized prostate cancer. A broad swath of specialists in the initial management of low-risk disease, as well as many in the patient advocacy community, have been highly critical of this change to the NCCN guidelines. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active, guidelines, low-risk, NCCN, surveillance | 10 Comments »
Posted on October 17, 2021 by Sitemaster
At the end of September, the Prostate Cancer Foundation appointed Charles {“Chuck”) Ryan, MD — formerly of the University of California, San Francisco, and the University of Minnesota — as the new President and CEO of the Foundation. And there will be two opportunities for patients to hear directly from Dr. Ryan in the near future. … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on September 22, 2021 by Sitemaster
Prostate Cancer International (PCaI) is proud to be an inaugural member of the new Prostate Cancer Impact Alliance (PCIA). PCIA’s shared vision is to advance education, research and equitable access to high quality care to better patient outcomes for men with prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: advocacy, alliance, outcome, PCIA | 5 Comments »
Posted on September 21, 2021 by Sitemaster
Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on June 5, 2021 by Sitemaster
As we’ve seen, brachy boost therapy seems to have the best oncological results for men with very high-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: ADT, brachy boost, high-risk, hormonal therapy, radiotherapy | 1 Comment »
Posted on June 3, 2021 by Sitemaster
Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by individual investigators, to SOC alone in the treatment of men with PSMA-positive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: 177Lu-PSMA-617. VISION, castration-resistant, mCRPC, metastatic, trial | 1 Comment »
Posted on May 19, 2021 by Sitemaster
It has always been troubling that only about half of all salvage radiation treatments after failure of radical prostatectomy are successful. Usually, only the prostate bed is treated. But sometimes recurrent patients (or those with persistently elevated PSA) receive salvage radiation to the pelvic lymph nodes as well, or subsequently. … READ MORE …
Filed under: Uncategorized | Tagged: dimensions, radiation, salvage | 15 Comments »
Posted on May 14, 2021 by Sitemaster
On Wednesday, May 26, the Cancer Support Community together with Prostate Cancer International will be holding the first of a series of six FREE educational webinars for patients and family members. … READ MORE …
Filed under: Uncategorized | 2 Comments »
Posted on April 23, 2021 by Sitemaster
For those who have not already heard about it, two of the very largest patient-centric prostate cancer advocacy organizations have agreed to merge into one.
… READ MORE …
Filed under: Uncategorized | Tagged: advocacy, support, Us TOO, ZERO | 3 Comments »
Posted on February 25, 2021 by Sitemaster
Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: combination, radium-223, therapy, Xofigo | Leave a comment »
Posted on December 3, 2020 by Sitemaster
If you are one of our readers who is really “into” the underlying causes of and development of prostate cancer, then you probably want to see if you can read a newly published article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Uncategorized | Tagged: epigenetics, evolution, genetrics, initiation, progression | 2 Comments »
Posted on November 13, 2020 by Sitemaster
THE "NEW" PROSTATE CANCER INFOLINK 